TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10912880
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren) administered orally two times a day for 27 consecutive days
Study: 9451346
Drug: 1.5% glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glycine irrigation solution at 70 cm height
Study: 9451346
Drug: 1.5% glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glycine irrigation solution at 150 cm height
Study: 31892533
Drug: NI-0101 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NI-0101 (5 mg/kg, every 2 weeks for 12 weeks)
Study: 20420907
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 mug taken twice daily for one week)
Study: 20420907
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) (200,000 IU weekly for 3 weeks)
Study: 20420907
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo weekly for 3 weeks)
Study: 12401856
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (12 mg before each dialysis session for 4 weeks)
Study: 2387279
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available preparations (yeast Se)
Study: 6803277
Drug: Pyridoxine plus
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine plus L-tryptophan
Study: 28522374
Drug: NNZ-2566 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNZ-2566 (doses ranged from 6.0 to 100mg/kg orally and 0.1 to 30mg/kg intravenously)
Study: 21091547
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vitamin C/kg feed
Study: 21091547
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg or 800 mg vitamin C/kg feed
Study: 21091547
Drug: 150‐800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐800 mg vitamin C/kg feed
Study: 16514568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age- and sex-matched cohort undergoing capsule endoscopy for suspected small bowel disease)
Study: 15485574
Drug: Bicarbonate-buffered Bicavera
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-buffered Bicavera solution
Study: 15485574
Drug: Lactate-containing Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-containing Balance solution
Study: 11145322
Drug: Zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (10 mg daily for 15 nights)
Study: 3663879
Drug: Theo-Dur 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur 450 mg b.i.d.
Study: 3663879
Drug: Theotrim 450
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theotrim 450 mg b.i.d.
Study: 29016868
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg twice daily for 12 weeks
Study: 20507310
Drug: PR-PASIII-PC (platelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-PASIII-PC (platelets stored in platelet additive solution with pathogen reduction)
Study: 20507310
Drug: PASIII-PC (platelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: PASIII-PC (platelets stored in platelet additive solution without pathogen reduction)
Study: 3044091
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir capsules, five times per day for five days
Study: 3044091
Drug: Topical 5
Normalized name: urea topical 50% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5 percent acyclovir in a modified aqueous cream base
Study: 3044091
Drug: Topical 5
Normalized name: urea topical 50% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5 percent acyclovir in a polyethylene base
Study: 3044091
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of oral acyclovir
Study: 28758078
Drug: Superoposterior transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superoposterior transforaminal epidural steroid injection (SP TFESI) with 1 mL of contrast material followed by steroid injection
Study: 26311810
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d creatine
Study: 26311810
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d creatine plus 400 μg/d folic acid
Study: 26311810
Drug: 400 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg/d folic acid
Study: 24063842
Drug: Diuretics in
Normalized name: OTHER DIURETICS in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics in patients with HFrEF
Study: 12492792
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Study: 12492792
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral block with the same analgesic mixture
Study: 12492792
Drug: Continuous intraarticular
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraarticular infusion of ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Study: 10692189
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg up to 2 mg)
Study: 9348574
Drug: UFT 400
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 400 mg/day for 6 months plus prednimustine 60 mg/m2 for 7 consecutive days, every 28 days in 6 cycles (arm B)
Study: 9348574
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 1 year plus UFT 400 mg/day for 6 months (arm B)
Study: 9348574
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 1 year (arm A)
Study: 8122356
Drug: Cisapride (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.1 mg/kg bw intramuscularly at 8‐h intervals)
Study: 3537899
Drug: Dyazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyazide (50 mg triamterene and 25 mg hydrochlorothiazide)
Study: 20164315
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (16.98 mg genistein and 5.40 mg daidzein aglycone equivalents per dose)
Study: 20164315
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement (5.27 mg genistein and 17.56 mg daidzein aglycone equivalents per dose)
Study: 18788506
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 g q12 h and clindamycin 900 mg q8 h (group 2)
Study: 18788506
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g q12 h and clindamycin 900 mg q8 h (group 1)
Study: 16128647
Drug: Implantable drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable drug delivery system (IDDS)
Study: 11892681
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment using TherMatrx TMx-2000
Study: 8088613
Drug: Standard-dose salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose salvage chemotherapy
Study: 7510351
Drug: 6 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 million kallikrein inactivator units of aprotinin (high-dose group)
Study: 7510351
Drug: 2 million
Normalized name: Carticel 12 million cells/vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 million kallikrein inactivator units of aprotinin (low-dose group)
Study: 7510351
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (high-dose, low-dose, control)
Study: 4395906
Drug: Isoprenaline 400
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline 400 μg
Study: 4395906
Drug: Other bronchodilator
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other bronchodilator aerosols (doses adjusted to match peak response of isoprenaline)
Study: 30312378
Drug: Method 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method 3 (weighted trial's subgroup-specific treatment effects)
Study: 23269773
Drug: Uncertainty management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty management intervention (scripted CD and guide booklet, supplemented by four scripted, 20-minute weekly training calls)
Study: 23269773
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control condition (four scripted, 20-minute weekly training calls)
Study: 17919835
Drug: Definitive radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiotherapy with or without concurrent chemotherapy
Study: 10230191
Drug: Naltrexone, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, 1.0 mg/kg, administered daily for 2 weeks
Study: 10230191
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered daily for 2 weeks
Study: 6411791
Drug: Intravenous mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mixture of eight essential l-amino acids, hypertonic dextrose, and vitamins
Study: 27659879
Drug: CSL112 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (6 g)
Study: 26563497
Drug: Salidroside (Sal)
Normalized name: Salicoside
DrugBank: Salicin (DB19357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salidroside (Sal) 20 mg/kg
Study: 26563497
Drug: Salidroside (Sal)
Normalized name: Salicoside
DrugBank: Salicin (DB19357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salidroside (Sal) 40 mg/kg
Study: 26563497
Drug: Clopidogrel (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (7.5 mg/kg)
Study: 23091157
Drug: T4 with
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 with commercially available synbiotic Duolac, containing 500 cfu of both Lactobacillus acidophilus and Streptococcus faecium with the addition of lactose (0.001 mg/embryo)
Study: 2672868
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine (5 mg)
Study: 17894913
Drug: Intramuscular diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diamorphine (5 mg)
Study: 9684386
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day buprenorphine
Study: 11906798
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day buprenorphine
Study: 11906798
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day buprenorphine
Study: 9684386
Drug: 16 mg/day
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/day buprenorphine
Study: 8210019
Drug: Low-dose epidural
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epidural anaesthesia using 0.375% bupivacaine
Study: 2702250
Drug: Alipase (P)
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alipase (P) - 9 capsules/day
Study: 21969870
Drug: Placebo (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Control group from the Vaccine Trial)
Study: 18098357
Drug: Mid-axial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-axial injection technique (MAI technique)
Study: 18098357
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection technique (CI technique)
Study: 16270608
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) via propofol and remifentanil infusion
Study: 16270608
Drug: Inhaled sevoflurane
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sevoflurane with incremental doses of fentanyl
Study: 2249378
Drug: labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (200 to 1600 mg/day)
Study: 3042356
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 to 100 mg/day)
Study: 7317247
Drug: Equipotent doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equipotent doses (UD95) of thiopentone
Study: 7317247
Drug: Equipotent doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equipotent doses (UD95) of Althesin
Study: 31202641
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg
Study: 23981722
Drug: Black seed
Normalized name: BLACK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black seed oil (40-80 mg/kg/day)
Study: 12575606
Drug: Sini Decoction
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sini Decoction (SND) treatment
Study: 12575606
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no SND treatment)
Study: 8201388
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide)
Study: 8622020
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (FAC)
Study: 3365530
Drug: Low-dose indomethacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indomethacin (50 mg/day) combined with paracetamol (4 g/day)
Study: 3365530
Drug: High-dose indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose indomethacin (150 mg/day)
Study: 30932313
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus (IR-T)
Study: 24775991
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin 3 mcg/kg
Study: 24775991
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin 1 mcg/kg
Study: 24775991
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mcg/kg)
Study: 18284597
Drug: RB006 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (0.75 mg kg(‐1) intravenous bolus) followed by RB007 (2:1 to 0.125:1 antidote/drug ratio, 1.5 mg kg(‐1) to 0.094 mg kg(‐1))
Study: 11837528
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy for aphasia following stroke
Study: 9522243
Drug: Topical isotretinoin
Normalized name: isotretinoin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isotretinoin gel 0.05%
Study: 9522243
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid cream 0.05%
Study: 385402
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of betamethasone dipropionate + betamethasone phosphate (Diprospan)
Study: 385402
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of methylprednisolone acetate (Depomedrol)
Study: 19453049
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with midazolam 0.1 mg/kg, propofol 1 mg/kg, and fentanyl 1 microg/kg intravenously
Study: 16442399
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g of soy stanols
Study: 14586625
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy (Hyperbaric oxygen) added to steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction
Study: 14586625
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction)
Study: 3679620
Drug: Dextromethorphan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (60 mg single dose) - Resilar
Study: 3679620
Drug: Dextromethorphan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (60 mg single dose) - Redol comp.
Study: 3679620
Drug: Dextromethorphan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (60 mg single dose) - Extuson
Study: 29845764
Drug: LE-tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: LE-tablet computer use
Study: 24199672
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural treatment (ICBT) supported by short face-to-face consultations (MoodGYM)
Study: 16969350
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant chemotherapy (UFT 400 mg day-1 for 1 year) in stage I patients (group B)
Study: 16969350
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by chemotherapy (cisplatin and vindesine followed by UFT) in stage II or IIIA patients (group D)
Study: 2897912
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg kg‐1)
Study: 18405411
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg kg‐1)
Study: 9649995
Drug: Rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.9 mg kg‐1)
Study: 8804380
Drug: Hepatitis C
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis C vaccine
Study: 3484960
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with leucovorin calcium rescue (23 patients)
Study: 3484960
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (19 patients)
Study: 22796761
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of CMAB001 at doses of 0.5, 1.0, or 2.0 mg/kg
Study: 22796761
Drug: Weekly subcutaneous
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injections of CMAB001 at a dose of 1.0 mg/kg for 7 weeks
Study: 20163324
Drug: Albuterol/ipratropium bromide
Normalized name: albuterol/ipratropium bromide 20/100 MCG/INHAL Metered Dose Inhalation Spray, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/ipratropium bromide combination therapy
Study: 19115911
Drug: SHAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAM treatment for 6 to 7 consecutive days
Study: 18396244
Drug: Antidepressant users
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant users (36.2% of participants, n = 50)
Study: 18396244
Drug: Other prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other prescription medications
Study: 11725980
Drug: Multipurpose solution
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multipurpose solution with HPMC
Study: 8384232
Drug: 0.1% RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% RA cream
Study: 8384232
Drug: 0.001% RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.001% RA cream
Study: 3609120
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg daily for 1 week
Study: 23932463
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg/d
Study: 23932463
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg/d
Study: 14504090
Drug: Itraconazole (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (intravenous 200 mg daily, or oral solution 2.5 mg/kg 3 times daily)
Study: 14504090
Drug: Fluconazole (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (intravenous or oral, 400 mg daily)
Study: 11342474
Drug: IL-6 genotype
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 genotype (‐174 G‐‐>C polymorphism)
Study: 9412794
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg tid
Study: 30203762
Drug: Ibandronate needle
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate needle therapy
Study: 30203762
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid needle therapy
Study: 27344665
Drug: Piribedil (150–300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (150–300 mg/day, three times daily)
Study: 18397687
Drug: Serlift (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serlift (50 mg)
Study: 18397687
Drug: Zoloft (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoloft (50 mg)
Study: 12371727
Drug: Ultrafiltration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration at 20 ml/h-1/kg-1 (group 1, n = 146)
Study: 12371727
Drug: Ultrafiltration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration at 35 ml/h-1/kg-1 (group 2, n = 139)
Study: 12371727
Drug: Ultrafiltration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration at 45 ml/h-1/kg-1 (group 3, n = 140)
Study: 9666415
Drug: Leflunomide 25
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide 25 mg once daily
Study: 9666415
Drug: Leflunomide 10
Normalized name: leflunomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 10 mg daily